Company: TDBCP
Filing Date: 2025-07-21
Form Type: 424B2
Source: 0001140361-25-026555
Chunk: 24

Company: TORONTO DOMINION BANK
Filing Date: 2025-07-21
Form: 424B2
Chunk 24
---
 located by reference to its SEC file number provided below. The graphs below set forth the information relating to the historical performance of each Reference Asset. The graphs below show the daily historical Closing Values of each Reference Asset for the periods specified. We obtained the information regarding the historical performance of each Reference Asset in the graphs below from Bloomberg Professional ®service (“Bloomberg”). The Closing Values may be adjusted by Bloomberg for corporate actions such as stock splits, public offerings, mergers and acquisitions, spin-offs, delistings and bankruptcy. We have not independently verified the accuracy or completeness of the information obtained from Bloomberg. The historical performance of each Reference Asset should not be taken as an indication of its future performance, and no assurance can be given as to the Final Value of any Reference Asset. We cannot give you any assurance that the performance of the Reference Assets will result in a positive return on your initial investment.

| TD SECURITIES (USA) LLC | P-17 |

| SPDR®S&P®Biotech ETF |

We have derived all information contained herein regarding the SPDR ®S&P ®Biotech ETF (the “XBI Fund”) and the target index, as defined below, from publicly available information. Such information reflects the policies of, and is subject to changes by, the XBI Fund’s investment adviser, SSGA Funds Management, Inc. (“SSGA” or the “investment adviser”) and the index sponsor of the target index, as defined below. The XBI Fund is one of the separate investment portfolios that constitute the SPDR ®Series Trust (“SPDR”). The XBI Fund seeks to provide investment results that correspond generally to the total return performance, before fees and expenses, of the S&P ®Biotechnology Select Industry™ Index (the “target index”). The target index seeks to measure the performance of the biotechnology segment of the U.S. equity market and includes companies that have been identified as biotechnology companies on the basis of general industry classification from a universe of companies defined by the S&P Total Market Index, comprising the biotechnology sub-industry. The target index is calculated, maintained and published by, S&P Dow Jones Indices LLC (the “index sponsor”). The index sponsor is under no obligation to continue to publish, and may discontinue or suspend the publication of, the target index at any time. Select information regarding the XBI Fund’s expense ratio and its top constituents, country, industry and/or sector weightings may be made available on the XBI Fund’s website. Expenses of the XBI Fund